Interleukin-9 is a cytokine with multiple functions, including the ability to activate group 2 innate lymphoid cells, which has been postulated to be therapeutically active in mouse models of arthritis. Similarly, interleukin-9 has been suggested to play an important role in tumor immunity. Here, we describe the cloning, expression, and characterization of three fusion proteins based on murine interleukin-9 and the F8 antibody, specific to the alternatively spliced EDA domain of fibronectin. EDA is strongly expressed in cancer and in various arthritic conditions, while being undetectable in the majority of healthy organs. Interleukin-9-based fusion proteins with an irrelevant antibody specific to hen egg lysozyme served as negative control in our study. The fusion proteins were characterized by quantitative biodistribution analysis in tumor-bearing mice using radioiodinated protein preparations. The highest tumor uptake and best tumor:organ ratios were observed for a format, in which the interleukin-9 moiety was flanked by two units of the F8 antibody in single-chain Fv format. Biological activity of interleukin-9 was retained when the payload was fused to antibodies. However, the targeted delivery of interleukin-9 to the disease site resulted in a modest anti-tumor activity in three different murine models of cancer (K1735M2, CT26, and F9), while no therapeutic benefit was observed in a collagen induced model of arthritis. Collectively, these results confirm the possibility to deliver interleukin-9 to the site of disease but cast doubts about the alleged therapeutic activity of this cytokine in cancer and arthritis, which has been postulated in previous publications.
GoswamiRKaplanMH.A brief history of IL-9. J Immunol2011;
186:3283–8
2.
NoelleRJNowakEC.Cellular sources and immune functions of interleukin-9. Nat Rev Immunol2010;
10:683–7
3.
SchmittEGermannTGoedertSHoehnPHuelsCKoelschSKühnRMüllerWPalmNRüdeE.IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol1994;
153:3989–96
4.
RenauldJCDruezCKermouniAHoussiauFUyttenhoveCVan RoostEVan SnickJ.Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci USA1992;
89:5690–4
TurnerJ-EMorrisonPJWilhelmCWilsonMAhlforsHRenauldJ-CPanzerUHelmbyHStockingerB.IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med2013;
210:2951–65
7.
KochSSopelNFinottoS.Th9 and other IL-9-producing cells in allergic asthma. Semin Immunopathol2017;
39:55–68
8.
HauberH-PBergeronCHamidQ.IL-9 in allergic inflammation. Int Arch Allergy Immunol2004;
134:79–87
9.
Vargas HumblinRTVégranEGhiringhelliFApetohF.L. TH9 cells in anti-tumor immunity. Semin Immunopathol2017;
39:39–46
10.
ChenNLuKLiPLvXWangX.Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol2014;
7:2319–23
11.
RenauldJCvan der LugtNVinkAvan RoonMGodfraindCWarnierGMerzHFellerABernsAVan SnickJ.Thymic lymphomas in interleukin 9 transgenic mice. Oncogene1994;
9:1327–32
12.
ZhangJWangWGengQ-RWangLChenX-QLiuC-CLvY.Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma. PLoS One2014;
9:e94637
13.
PurwarRSchlapbachCXiaoSKangHSElyamanWJiangXJettenAMKhourySJFuhlbriggeRCKuchrooVKClarkRAKupperTS.Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med2012;
18:1248–53
14.
D, ThiVAParkSMLeeHKimYS.Ectopically expressed membrane-bound form of IL-9 exerts immune-stimulatory effect on CT26 Colon carcinoma cells. Immune Netw2018;
18:e12
15.
WangJSunMZhaoHHuangYLiDMaoDZhangZZhuXDongXZhaoX.IL-9 exerts antitumor effects in colon cancer and transforms the tumor microenvironment in vivo. Technol Cancer Res Treat2019;
18:1533033819857737.
16.
RauberSLuberMWeberSMaulLSoareAWohlfahrtTLinN-YDietelKBozecAHerrmannMKaplanMHWeigmannBZaissMMFearonUVealeDJCañeteJDDistlerORivelleseFPitzalisCNeurathMFMcKenzieANJWirtzSSchettGDistlerJHW.Ramming A. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med2017;
23:938–44
17.
NeriDSondelPM.Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol2016;
40:96–102
18.
BootzFNeriD.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today2016;
21:180–9
19.
PascheNNeriD.Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today2012;
17:583–90
20.
VenetzDHessCLinCAebiMNeriD.Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies. Proc Natl Acad Sci USA2015;
112:2000–5
21.
VillaATrachselEKasparMSchliemannCSommavillaRRybakJ-NRösliCBorsiLNeriD.A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer2008;
122:2405–13
22.
RybakJ-NTrachselEScheuermannJNeriD.Ligand-based vascular targeting of disease. Chem Med Chem2007;
2:22–40
23.
SchwagerKVillaARösliCNeriDRösli-KhabasMMoserG.A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol2011;
3:25
24.
SchliemannCPalumboAZuberbühlerKVillaAKasparMTrachselEKlapperWMenssenHDNeriD.Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood2009;
113:2275–83
25.
GutbrodtKLSchliemannCGiovannoniLFreyKPabstTKlapperWBerdelWENeriD.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med2013;
5:201ra118
26.
SchwagerKBootzFImeschPKasparMTrachselENeriD.The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Hum Reprod2011;
26:2344–52
27.
SchwagerKKasparMBootzFMarcolongoRParesceENeriDTrachselE.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther2009;
11:R142
28.
BootzFVenetzDZiffelsBNeriD.Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12. Protein Eng Des Sel2016;
29:445–55
29.
PrettoFEliaGCastioniNNeriD.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother2014;
63:901–10
30.
PascheNWulhfardSPrettoFCarugatiENeriD.The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res2012;
18:4092–103
31.
HemmerleTDollFNeriD.Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis. Proc Natl Acad Sci USA2014;
111:12008–12
32.
HemmerleTZgraggenSMatasciMHalinCDetmarMNeriD.Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation. J Dermatol Sci2014;
76:96–103
33.
DollFSchwagerKHemmerleTNeriD.Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther2013;
15:R138
34.
BootzFZiffelsBNeriD.Antibody-based targeted delivery of interleukin-22 promotes rapid clinical recovery in mice with DSS-Induced colitis. Inflamm Bowel Dis2016;
22:2098–105
35.
BruijnenSTGChandrupatlaDMSHGiovanonniLNeriDVugtsDJHuismanMCHoekstraOSMustersRJPLammertsmaAAvan DongenGAMSJansenGMolthoffCFMvan der LakenCJ.F8-IL10: a new potential antirheumatic drug evaluated by a PET-Guided translational approach. Mol Pharm2019;
16:273–81
36.
HackerDLKiseljakDRajendraYThurnheerSBaldiLWurmFM.Polyethyleneimine-based transient gene expression processes for suspension-adapted HEK-293E and CHO-DG44 cells. Protein Exp Purif2013;
92:67–76
37.
PfaffenSFreyKStutzIRoesliCNeriD.Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur J Nucl Med Mol Imaging2010;
37:1559–65
MoselySISPrimeJESainsonRCAKoopmannJ-OWangDYQGreenawaltDMAhdesmakiMJLeylandRMullinsSPacelliLMarcusDAndertonJWatkinsACoates UlrichsenJBrohawnPHiggsBWMcCourtMJonesHHarperJAMorrowMValge-ArcherVStewartRDovediSJWilkinsonRW.Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res2017;
5:29–41
40.
CarnemollaBBorsiLBalzaECastellaniPMeazzaRBerndtAFerriniSKosmehlHNeriDZardiL.Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood2002;
99:1659–65
41.
HalinCRondiniSNilssonFBerndtAKosmehlHZardiLNeriD.Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol2002;
20:264–9
42.
EbbinghausCRoncaRKasparMGrabulovskiDBerndtAKosmehlHZardiLNeriD.Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer2005;
116:304–13
43.
PedrettiMRancicZSoltermannAHerzogBASchliemannCLachatMNeriDKaufmannPA.Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies. Atherosclerosis2010;
208:382–9
44.
PucaEProbstPStringhiniMMurerPPellegriniGCazzamalliSHutmacherCGouyouBWulhfardSMatasciMVillaANeriD.The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors. Int J Cancer2020;
146:2518–30
45.
SchwagerKHemmerleTAebischerDNeriD.The immunocytokine L19–IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol2013;
133:751–8
46.
PogueSLTauraTBiMYunYShoAMikesellGBehrensCSokolovskyMHallakHRosenstockMSanchezEChenHBerensonJDoyleANockSWilsonDS.Targeting attenuated interferon-α to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-Target activity. PLoS One2016;
11:e0162472
47.
CauwelsAVan LintSGarcinGBultinckJPaulFGerloSVan der HeydenJBordatYCatteeuwDDe CauwerLRoggeEVerheeAUzéGTavernierJ.A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncoimmunology2017;
7:e1398876
48.
HessCNeriD.The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity. Cancer Immunol Immunother2015;
64:635–44
49.
HessCNeriD.Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6. Protein Eng Des Sel2014;
27:207–13
50.
HemmerleTNeriD.The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo. Cancer Immunol Res2014;
2:559–67
51.
HutmacherCNúñezNGLiuzziARBecherBNeriD.Targeted delivery of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK and CD8+ T cells. Cancer Immunol Res2019;
7:572–83
52.
HemmerleTProbstPGiovannoniLGreenAJMeyerTNeriD.The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer2013;
109:1206–13
53.
WanJWuYJiXHuangLCaiWSuZWangSXuH.IL-9 and IL-9-producing cells in tumor immunity. Cell Commun Signal2020;
18:50
54.
ChenTGuoJCaiZLiBSunLShenYWangSWangZWangZWangYZhouHCaiZYeZ.Th9 cell differentiation and its dual effects in tumor development. Front Immunol2020;
11:1026.
55.
LeeJEZhuZBaiQBradyTJXiaoHWakefieldMRFangY.The role of interleukin-9 in cancer. Pathol Oncol Res2020;
26:2017–22
56.
SchmittEKleinMBoppT.Th9 cells, new players in adaptive immunity. Trends Immunol2014;
35:61–8
57.
RamadanAGriesenauerBAdomDKapurRHanenbergHLiuCKaplanMHPaczesnyS.Specifically differentiated T cell subset promotes tumor immunity over fatal immunity. J Exp Med2017;
214:3577–96
58.
HuBQiu-LanHLeiR-EShiCJiangH-XQinS-Y.Interleukin-9 promotes pancreatic cancer cells proliferation and migration via the miR-200a/beta-catenin axis. Biomed Res Int2017;
2017:2831056
59.
TianLLiYChangRZhangPZhangJHuoL.Lentiviral vector-mediated IL-9 overexpression stimulates cell proliferation by targeting c-myc and cyclin D1 in colitis-associated cancer. Oncol Lett2019;
17:175–82
60.
YeZ-JZhouQYinWYuanM-LYangW-BXiongX-ZZhangJ-CShiH-Z.Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med2012;
186:1168–79
61.
ParkSMDo-ThiVALeeJ-OLeeHKimYS.Interleukin-9 inhibits lung metastasis of melanoma through stimulating anti-tumor M1 macrophages. Mol Cells2020;
43:479–90
62.
FreyKZivanovicASchwagerKNeriD.Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integr Biol2011;
3:468–78
63.
ZiffelsBGrötschAAl-BayatiLNeriD.Targeted delivery of calreticulin to ED-a fibronectin leads to tumor-growth retardation. J Biotechnol2019;
290:53–8
64.
PascheNFreyKNeriD.The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate. Angiogenesis2012;
15:165–9
65.
De LucaRGouyouBOngaroTVillaAZiffelsBSanninoAButtinoniGGaleazziSMazzacuvaMNeriD.A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas. Front Oncol2019;
9:1228
66.
HalinCGafnerVVillaniMEBorsiLBerndtAKosmehlHZardiLNeriD.Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor α. Cancer Res2003;
63:3202–10
67.
OmataYFrechMPrimbsTLucasSAndreevDScholtysekCSarterKKindermannMYeremenkoNBaetenDLAndreasNKamradtTBozecARammingAKrönkeGWirtzSSchettGZaissMM.Group 2 innate lymphoid cells attenuate inflammatory arthritis and protect from bone destruction in mice. Cell Rep2018;
24:169–80
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
